Brief: Vectivbio And Asahi Kasei Pharma Announce The Start Of A Phase 1 Study Of Apraglutide In Japan
13/03/2023 12:23
March 13 (Reuters) - Asahi Kasei Corp 3407.T :
* VECTIVBIO AND ASAHI KASEI PHARMA ANNOUNCE THE START OF A
PHASE
1 STUDY OF APRAGLUTIDE IN JAPAN
Source text for Eikon: ID:nGNXX5gw0
Further company coverage: 3407.T
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on VectivBio Holding AG
See all newsBrief: Ironwood And VectivBio Announce Expiration Of Hart-Scott-Rodino Waiting Period For Proposed Acquisition Of VectivBio
Brief: Ironwood Pharmaceuticals Says If Deal Aborts, VectivBio To Pay Termination Fee
U.S. STOCKS ON THE MOVE-Pfizer, Zoom Video, American Airlines
U.S. STOCKS ON THE MOVE-Atea Pharma, Microbot Medical, Krystal
U.S. STOCKS ON THE MOVE-NuScale Power Corp, Foot Locker, Greenhill